Zolmitriptan is a selective serotonin receptor agonist of the 1B and 1D subtypes. It is a triptan, used in the acute treatment of migraine attacks with or without aura and cluster headaches.
Zolmitriptan is marketed by AstraZeneca with the brand names Zomig, Zomigon (Argentina, Canada & Greece), AscoTop (Germany) and Zomigoro (France). In 2008, Zomig generated nearly $154 million in sales.
AstraZeneca's U.S. patent on Zomig tablets expired on November 14, 2012, and its pediatric exclusivity extension expired on May 14, 2013. The patent in certain European countries has already expired too, and generic drug maker Actavis released a generic version in those countries, starting in March 2012.

Chemical Name	zolmitriptan
Synonyms	(S)-4-[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone;Zolmitriptan;(4R)-4-[[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one;
CAS No.	139264-17-8
Molecular Formula	C16H21N3O2
Molecular Weight	287.35700
PSA	57.36000
LogP	2.25170

Appearance & Physical State	White or kind of white powder
Density	1.217 g/cm3
Boiling Point	563.3ºC at 760 mmHg
Melting Point	136-141ºC
Flash Point	294.5ºC
Refractive Index	1.619
Storage Condition	Store in original container in a cool dark place.
Vapor Pressure	1.03E-12mmHg at 25°C

Safety Statements	S26-S36
HS Code	2934999090
Risk Statements	R36/37/38
Hazard Codes	Xi